Qiagen

ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN

Sunday, November 10, 2019 - 4:00pm

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. (NYSE: QGEN) resulting from allegations that Qiagen may have issued materially misleading business information to the investing public.

Key Points: 
  • Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. (NYSE: QGEN) resulting from allegations that Qiagen may have issued materially misleading business information to the investing public.
  • Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Qiagen investors.
  • Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Global HPV Testing & PAP Test Market Analysis Report, 2019-2024 - Key Players are Abbott Laboratories, Qiagen, Becton, Dickinson & Company, and Roche - ResearchAndMarkets.com

Wednesday, November 6, 2019 - 8:17pm

The "HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing & PAP Test Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Therefore the increasing number of cases of cervical cancer has boosted the demand for HPV testing and PAP testing market.
  • Thus the increasing number of cervical cancer cases has boosted the demand for HPV testing and Pap testing market.
  • Some key players in the HPV test and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, Roche and many others.

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of QIAGEN N.V.

Wednesday, November 6, 2019 - 3:20pm

NEW YORK,, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky reminds investors that it has commenced an investigation of QIAGEN N.V. (QIAGEN or the Company) (NYSE: QGEN) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK,, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky reminds investors that it has commenced an investigation of QIAGEN N.V. (QIAGEN or the Company) (NYSE: QGEN) concerning possible violations of federal securities laws.
  • On October 8, 2019, QIAGEN filed multiple press releases in its Form 6-K filed with the Securities and Exchange Commission.
  • In these releases, the Company disclosed that its longtime Chairman and CEO Peer Schatz had retired abruptly.
  • The firms attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.

QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting

Wednesday, November 6, 2019 - 6:30am

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using next-generation sequencing (NGS) technologies.

Key Points: 
  • QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using next-generation sequencing (NGS) technologies.
  • This unmatched low-input solution reduces a typical 2-3 day workflow to approximately only nine hours by eliminating the need for two separate time-consuming, inefficient and costly workflows for library preparation from separate DNA and RNA samples.
  • Both libraries are generated from the same sample input, sample utilization and, in turn, sampling-induced bias is also reduced.
  • For more information about QIAGENs presence at AMP 2019, please visit amp.qiagen.com .

QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers

Tuesday, November 5, 2019 - 9:05pm

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for precision medicine in immuno-oncology, in particular based on the powerful next-generation sequencing (NGS) technology.

Key Points: 
  • QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for precision medicine in immuno-oncology, in particular based on the powerful next-generation sequencing (NGS) technology.
  • QIAGEN intends to highlight these new agreements and other elements of its oncology portfolio at the Association for Molecular Pathology (AMP) Annual Meeting, which is being held from November 7-9 in Baltimore, Maryland.
  • Additionally, QIAGEN has entered into a new licensing agreement with researchers at the University of Bonn in Germany for novel epigenomic biomarkers based on immune checkpoint gene methylation, including CTLA4, PD-L1 and PD1, with rights to co-develop predictive companion diagnostics.
  • QIAGEN has non-exclusive rights to develop and globally commercialize companion diagnostics and other IVD kits to be used together with Illuminas MiSeq Dx and NextSeq 550Dx Systems.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Qiagen (QGEN) Investors with Significant Losses to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

Saturday, November 2, 2019 - 12:10am

SAN FRANCISCO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds Qiagen N.V. (NYSE: QGEN) investors of the firms ongoing investigation of possible violations of federal securities laws.

Key Points: 
  • SAN FRANCISCO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds Qiagen N.V. (NYSE: QGEN) investors of the firms ongoing investigation of possible violations of federal securities laws.
  • The investigation centers on whether Qiagen misrepresented or concealed regional demand for its molecular and genetic testing applications.
  • Were focused on investors losses and whether Qiagen falsely portrayed demand for its products, said Hagens Berman partner Reed Kathrein.
  • Hagens Berman is a national law with nine offices in eight cities around the country and eighty attorneys.

QIAGEN Reports Full Results for Third Quarter and First Nine Months of 2019

Wednesday, October 30, 2019 - 8:05pm

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2019.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2019.
  • QIAGEN revised its outlook for full-year 2019 sales to about 4% CER growth, and tightened the outlook for adjusted earnings per share (EPS) to the upper end of the previous range to $1.43-1.44 CER.
  • We are maintaining a sharp focus on operating efficiencies and disciplined capital allocation to support growth and increase returns.
  • The majority of the restructuring charges taken in the third quarter of 2019 involve non-cash items related to ending development of new NGS-based instruments.

QIAGEN’s QuantiFERON®-TB Gold Plus Test Added to the Global Drug Facility Catalog for Public Health Efforts

Tuesday, October 29, 2019 - 9:05pm

The GDF is the largest provider to the public sector of quality-assured tuberculosis medicines, diagnostics and laboratory supplies.

Key Points: 
  • The GDF is the largest provider to the public sector of quality-assured tuberculosis medicines, diagnostics and laboratory supplies.
  • Operating a unique pooled procurement system, the GDF facilitates access and helps match demand for TB diagnostics and drugs with funding from donors, governments and non-governmental organizations.
  • The acceptance of QFT-Plus for the GDF catalog advances QIAGENs strategy to help expand screening with modern blood-based assays for latent TB infection in regions with a high disease burden but limited resources.
  • In addition, QIAGEN is working with the World Health Organization (WHO), governments and NGOs (non-governmental organizations) in the global fight to eradicate TB.

QIAGEN (QGEN) Alert: Johnson Fistel Launches Investigation into QIAGEN N.V.; Investors Encouraged to Contact Firm

Tuesday, October 22, 2019 - 11:00am

SAN DIEGO, Oct. 22, 2019 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against QIAGEN N.V. ("QIAGEN" or the "Company") (NYSE: QGEN) for violations of federal securities laws.

Key Points: 
  • SAN DIEGO, Oct. 22, 2019 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against QIAGEN N.V. ("QIAGEN" or the "Company") (NYSE: QGEN) for violations of federal securities laws.
  • The firm is investigating whether QIAGEN made misrepresentations and/or concealed information regarding regional demand for its molecular and testing applications.
  • On October 7, 2019, QIAGEN warned that Q3 2019 net sales growth would be significantly lower than initial projections, which the Company attributed to weaker-than-expected developments in China.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia.

QIAGEN to Report Results for Q3 and First Nine Months Of 2019

Monday, October 21, 2019 - 2:48pm

QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter and first nine months of 2019 on Wednesday, October 30 at approximately 21:05 Central European Time (CET) / 16:05 Eastern Standard Time (EDT).

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter and first nine months of 2019 on Wednesday, October 30 at approximately 21:05 Central European Time (CET) / 16:05 Eastern Standard Time (EDT).
  • A conference call is planned for Thursday, October 31, at 14:00 CET / 9:00 EDT hosted by Thierry Bernard, Interim Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
  • (For Europe: Due to the U.S. time switch, distribution of our Q3 report and the timing of our investor conference call (14:00 instead of 15:00) will be held one hour earlier than usual.)
  • The conference call will begin at 14:00 CET / 9:00 EDT on Thursday, October 31, 2019.